The treatment of peptic ulcer disease has undergone a revolution in the past decade. This revolution, based on advances in cellular biology, pharmacology, and health care delivery, has changed forever the treatment of this major disease. An improved understanding of the regulation and cellular mechanisms of gastric acid secretion has resulted in the development of specific and potent drugs for the treatment of peptic ulcer. These new agents permit clinicians to affect, at specific points, the abnormal secretory and mucosal defense mechanisms associated with peptic ulceration. Of the new agents, the histamine Hz-receptor antagonists are currently the most important.
While the incidence of peptic ulcer has been declining in the United States since the mid 196Os, the introduction of effective Hz-receptor antagonists led to a further, precipitous fall in patients referred for elective peptic ulcer surgery. tntractability as an indication for operative therapy has become exceedingly rare. Indeed, the circumstances that constitute failure of medical therapy or are indications for surgical therapy in this cimetidine era have yet to be clearly defined.
The contribution of the Hz-receptor antagonists and other newer antisecretory drugs to the improved treatment of patients with peptic ulcer disease cannot be overestimated, and yet, future improvements appear likely. An important milestone in the development of potent antisecretory drugs may have been achieved with the synthesis of proton-pump inhibitors. As will be discussed, the evidence is unequivocal that these new agents effectively relieve ulcer pain, promote healing, and reduce short-term ulcer morbidity. It must be pointed out, however, that none of the antisecretory drugs developed to date have been shown to alter the natural history of peptic ulcer disease, i.e., the ulcer diathesis. Currently available agents are essentially palliative; they promote healing of ulcers but do not cure ulcer disease. The next important milestone in the treatment of peptic ulcer disease will be the discovery of drugs which permanently alter the ulcer diathesis.
The purposes of this presentation will be: (11 to discuss the regu-lation and cellular mechanisms of acid secretion; (2) to classify drugs used in ulcer therapy according to their sites and mechanisms of action; (3) to discuss the important drugs with respect to their pharmacokinetics, clinical efficacy, and side effects; and (4) to provide a perspective for use of the various agents in peptic ulcer disease and to examine the present and future impact of new drugs on surgery for peptic ulcer disease.
REGULATION OF GASTRIC ACID SECRETION
Gastric acid secretion is regulated through a complex interaction of nerves, hormones, and local or paracrine agents (Fig 11 . with the gastric lumen. These neurohumoral mechanisms serve to modulate both inhibitory and stimulatory processes.l The human stomach normally contains about 1 billion parietal cells. The parietal cell secretes acid continuously both in the basal and fasting state. The mechanisms underhying this basal acid secretion are poorly understood.
In general, we have a better understanding of the processes that stimulate acid secretion than of those that inhibit it.
BASAL ACID SECRETION
The normal human stomach secretes 2 to 5 mEq of HCI per hour in the fasting state. Since vagotomy decreases this basal secretion by some 85%, it has been presumed that vagal tone is important in determining the rate of basal acid production. However, Hz-receptor blockers have also been demonstrated to inhibit basal acid secretion by about 80%. One might conclude, therefore, that ambient histamine concentration in the interstitial fluid bathing the parietal cell as well as vagal tone are important in sustaining basal acid secretion. Gastrin does not appear to play an important role in basal acid secretion in normal individuals.
Patients with the Zollinger-Ellison syndrome, however, may secrete in excess of 10 mEq of acid per hour in the fasting state and, in this pathological condition, basal acid secretion is stimulated by gastrin. Critically ill patients, particularly those who are septic or have increased intracranial pressure, will also have increased "basal" acid secretion.
STIMULATED ACID SECRETION
Phasic vagal discharge in response to the thought, sight, or smell of food stimulates acid secretion directly by a cholinergic mechanism. Vagal discharge also inhibits gastric somatostatin release. Since somatostatin inhibits parietal cell secretion, inhibition of somatostatin release may be an additional mechanism by which the vagus stimulates acid secretion. The direct cholinergic action of the parietal cell has the more important role, however. The cephalic phase component of acid secretion, as determined by sham-feeding of normal individuals, is about 10 mEq/hr. This vagally controlled component of acid secretion represents approximately 40% of the maximal acid response to gastrin infusion.
When food enters the stomach, distention triggers neural reflexes and gastrin release is activated. A technique of continuous intragastric titration can be used to estimate the amount of acid the stomach secretes in response to a meal. These estimates range from 15 to 25 mEq/hr, or approximately 75% of maximal response to exogenous gastrin or histamine.
The reason that the maximal response to a meal is somewhat lower than the response to exogenous stimulants may be the concomitant release of somatostatin by food. Gastrin is the most important mediator of the gastric phase of acid secretion. It is of interest that women secrete twice as much gastrin as men in response to food. Since their meal-stimulated acid response is equal to or less than that of men, the parietal cells in women may be less sensitive to gastrin. The reason for these differences is unknown.
When food enters the small intestine, an additional mechanism for acid secretion is activated. The "intestinal phase hormone" OI "enterooxyntin" is released. Purification and chemical characterization of this putative hormone has not been accomplished.
Physiological studies suggest that although enterooxyntin is a weak stimulant of acid secretion, it is capable of markedly augmenting the acid response to both submaximal and maximal doses of gastrin and histamine.
INHIBITION OF ACID SECBETION
Inhibitor?/ regulation of gastric acid secretion is accomplished through central, vagal, gastric, intestinal, and colonic mechanisms.
A number of neuropeptides, most importantly bombesin or gastrin-releasing peptide, cause profound inhibition of gastric acid secretion when administered into the lateral cerebral ventricles of rats and dogs. Whether these centrally inhibiting neuropeptides play a physiological role in inhibiting the regulation of acid secretion in humans has not been established. The vagus appears to exert a dual control of acid secretion and gastrin release, modulating both stimulatory and inhibitory actions. After vagotomy, fasting and postprandial plasma gastrin levels increase, indicating that the vagus normally exerts tonic inhibitory regulation on gastrin release. The vagal fibers to the oxyntic mucosa appear to mediate this inhibition.
In animals, sham-feeding inhibits pentagastrin-stimulated acid secretion, implying that vagal activation by sham-feeding causes the release of an inhibitory substance. The imputed vagal inhibitor has been referred to as "vagogastrone."
The inhibition of gastric acid secretion relies on negative feedback inhibition of gastrin release by acid and on other neurohumoral mechanisms.
When gastric pH falls to 2.0, gastrin release ceases. Somatostatin may be an important mediator of this negative feedback loop. In addition, somatostatin is a dominant paracrine agent within the gastric wall to modulate both the release of gastrin from the antrum and the secretion of HC from the oxyntic mucosa. The release of somatostatin is reciprocally linked to that of gastrin; stimulation of somatostatin release is associated with inhibition of gastrin release. Other neuropeptides, contained within vagal fibers in the gastric wall, may also play an inhibitory role. Calcitonin-gene-related peptide and substance P are two of many neuropeptides which may be important in modulating acid secretion. Additionally, other neuroendocrine substances, whose release from the oxyntic mucosa are under vagal control, may subserve inhibitory functions. Ulcer recurrence after proximal gastric vagotomy has been postulated to be partly due to interference in the release of these inhibitors of acid secretion.
Intestinal phase inhibition occurs when acid, fat, and hyperosmolar solutions enter the intestine. Acid in the upper intestine releases secretin and another inhibitory agent (bulbogastrone) from the duodenal bulb. High doses of secretin have been demonstrated to inhibit gastric acid secretion, although there is some debate as to whether secretin plays a physiologically-important inhibitory role during normal digestion. Other inhibitory peptides released from the small intestine include gastric inhibitory peptide, somatostatin, neurotensin, and peptide YY (PYY). Each of these agents has been demonstrated to inhibit acid secretion. PYY and another humoral agent yet to be isolated tcologastronel are also released from the colonic mucosa. It is possible that all of the intestinal and colonic inhibitors act synergistically to turn off acid secretion after a meal.
CELLULAR MECHANISMS OF ACID SECRETION
Three "on switches" are present in the basolateral membrane of the acid-secreting parietal cell (Fig 2) . These are specific receptors for histamine, acetylcholine, and gastrin.' When histamine occupies the HZ-receptor, a membrane-bound enzyme, adenylate cyclase, is activated.
This activated enzyme converts ATP into cyclic AMP, which then acts as the secondary, intracellular messenger. Increased intracellular cyclic AMP results in a cascade of intracellular events including, sequentially, activation of protein-C kinase, protein phosphorylation, and stimulation of the H+-Kf -ATPase proton pump, located on the secretory or canalicular membrane of the parietal cell. The proton pump is a unique enzyme system in the plasma membrane of the parietal cell, which causes the secretion of H' into the lumen of the secretory canaliculus in exchange for K+ against a steep electrochemical gradient. Within the secretory canaliculus, the pH approximates 1. This process represents the final common pathway by which all stimulants affect acid secretion.
When acetylcholine and gastrin occupy their respective receptors, the initial cascade of intracellular events activated is different. sociated with the rough endoplasmic reticulum and later by influx of extracellular calcium. Thus, calcium is the secondary intracellular messenger for the actions of gastrin and acetylcholine.
Different protein-kinases are subsequently activated for gastrin or acetylcholine, but the final steps of phosphorylation and activation of the H+-K+-ATPase are probably the same for both agents.
It is clear that several classes of drugs that specifically inhibit acid secretion could be developed:
those that block the cell-surface receptors for histamine, gastrin, or acetylcholine, those that interfere with intracellular processes, and, finally, those that block the proton pump. Receptor antagonists for histamine, gastrin, or acetylcholine and proton pump inhibitors would be expected to have important advantages in terms of specificity. The revolution in therapy for patients with peptic ulcer has occurred because of the availability of drugs with these characteristics.
However, since similar intracellular pathways are utilized by many tissues for generation of second messengers and for intracellular protein phosphotylation, it is unlikely that drugs that selectively inhibit the intracellular processes of the parietal cell will have clinical utility. Figure 3 depicts the drugs used in peptic ulcer therapy according to their site of action. As a result of these molecular rearrangements, a series of compounds has been produced with increasing potency and efficacy. In addition, the pharmacokinetics have been modified so that H,-receptor antagonism has been prolonged up to and beyond 24 to 48 hours. In addition, some of the newer compounds display very tight binding to receptors with an almost insurmountable antagonism. The pharmacokinetics of single doses of cimetidine and ranitidine have been studied after intravenous and oral administration in normal subjects and after oral administration in patients with duodenal ulcer. Steady-state pharmacokinetics have also been reported in normal subjects and patients with duodenal ulcers receiving therapeutic doses of the drugs. Except for a modest difference in effects on hepatic microsomal enzymes, the pharmacokinetics of ranitidine are generally quite similar to those of cimetidine.
SITES OF ACTION OF ANTI-ULCER DRUGS
From a pharmacokinetic standpoint, the choice between these two agents is quite arbitrary.
Plasma concentrations of cimetidine and ranitidine peak 1 to 3 hours after oral ingestion3"""
The mean bioavailability of 200 mg of oral cimetidine ranges from 63% to 78%. A wider range of values are reported for the bioavailability of orally administered ranitidine, varying from 39% to 87%. The elimination half-life of intravenously administered cimetidine has been reported to be 2.1 to 3.1 hours. Ranitidine has a slightly shorter elimination half-life after intravenous administration of 1.6 to 2.1 hours. Total plasma clearance is similar for both drugs, averaging approximately 600 mUmin. Both cimetidine and ranitidine, along with their products of metabolism, are secreted in the urine. Approximately 50% of the administered dose is recovered unchanged in the urine within 24 hours, with the major portion of urinary excretion occurring during the first 6 hours after administration.
Chronic renal failure significantly prolongs plasma clearance.31 A small, but not insignificant, fraction of the drug is eliminated in bile. Modest degrees of hepatic dysfunction have little effect on elimination of cimetidine or ranitidine; however, severe liver dysfunction prolongs the drug half-life. Approximately 3% of cimetidine is recovered unchanged in the feces. Many studies have demonstrated a direct correlation between plasma concentration of HZ-receptor antagonists and inhibition of intragastric acidity. The 50% inhibition of pentagastrin-stimulated gastric acid secretion has been commonly used as one bioassay of drug efficacy. The serum concentration of cimetidine that inhibits pentagastrin-stimulated acid secretion by 50% (IC,,,) has been studied in both healthy subjects and in patients with duodenal ulcers. After intraduodenal administration, the I&, of ranitidine was 93.6 rig/ml in a study reported by Peden et a1.35 Lebert and co-workers have reported that the mean peak concentration of ranitidine associated with the 50% suppression of hydrogen ion output was 165 rig/ml."" The IC,, of cimetidine is higher. Two well-controlled studies on human subjects have reported values of 500 rig/ml and 780 rig/ml."', 3X The lower IC,, of ranitidine as compared to cimetidine is a reflection of its increased potency. Cimetidine and ranitidine have both been shown to suppress basal acid secretion as well as secretion stimulated (by histamine, peptone, or a standard meal) in a dose-dependent manner. On a molar basis, ranitidine is six to eight times more potent than cimetidine;
however, in clinical practice, this difference is not important. Equivalent degrees of acid suppression are easily obtained with equipotent intravenous doses of these agents (cimetidine 300 mg every 6 to 8 hours vs. ranitidine 50 mg every 6 to 8 hours). Single intravenous doses of cimetidine (300 mgl and ranitidine (50 mg) produce equivalent acid suppression in terms of gastric pH, secretory volume, titratable acidity, and total acid ouput3' Both regimens increase intragastric pH above 3.5 within 30 minutes with maintenance at this level for 3 to 4 hours.
Currently, when oral administration is not possible, most patients receive intravenous HZ-receptor antagonists by intermittent bolus administration.
However, recent evidence suggests that the continuous infusion of cimetidine is likely to be associated with significant advantages. Ostro and coworkers have reported that the primed, continuous infusion of cimetidine was more effective than bolus delivery in maintaining serum drug concentrations above 0.5 @ml and in keeping gastric pH values above 4.0."' Twenty-three patients in a medical intensive care unit were examined in this randomized crossover trial. In the bolus regimen, patients received 300 mg intravenous cimetidine every 8, 6, or 4 hours as needed to keep gastric pH above 4.0. If increasing frequency of dosing was ineffective in maintaining the desired pH, the dose was raised to 400 mg every 4 hours. In the primed infusion regimen, an intravenous bolus of 300 mg was followed by a continuous infusion of 37.5 mghour. If gastric pH was not maintained above 4.0, the infusion rate was increased to 50, 75, and, finally, 100 mghour.
Intragastric pH values were maintained above 4.0 in 87% of patients receiving primed continuous infusions of up to 50 mghour, while pH values were maintained above 4.0 in only 22% of patients receiving intermittent boluses of 300 mg every 6 hours. Total drug doses were significantly lower with primed continuous infusions; in addition, therapeutic serum levels of cimetidine were more easily obtained with this regimen. Serum concentrations of cimetidine typically decreased below the therapeutic range of 0.5 kg/ml 4.3 hours after a 300 mg bolus. In contrast, serum concentrations of cimetidine were maintained above this level for 12 hours, when a 300-mg bolus was followed by continuous infusion of 37.5 mg/hour. To date, clinically important expression of such lymphocyte interactions has not been reported.'" Agranulocytosis and thrombocytopenia, which occur rarely with cimetidine, has also been reported with ranitidine." Cimetidine also binds avidly to receptors of the hepatic microsomal oxidase system. As a result of this interaction, cimetidine increases the blood levels and pharmacologic effects of drugs that de-pend on hepatic metabolism.
Such medications include warfarin, phenytoin, diazepam, propranolol, theophylline, and chlormethiazole.+"" Dosage adjustments must be made for these and other similarly metabolized drugs when cimetidine therapy is employed. Interactions with warfarin, theophylline, and phenytoin have been shown to be clinically significant. Kanitidine has less effect on hepatic transformation of therapeutic agents, although it does interact with the oxidase system. In addition to inhibiting the hepatic microsomal enzyme system, cimetidine and ranitidine also decrease hepatic blood flow,55. 5ti
The decrease in hepatic blood flow caused by these HZ-
Cimetidine binds to androgen receptors, and the intravenous administration of cimetidine consistently produces increases in serum prolactin levels."7 Galactorrhea is occasionally noted with prolonged use of this medication.
Gynecomastia has been reported in approximately 4% of patients treated with long-term high doses of cimetidine."X Kanitidine is also believed to interact with testosterone receptors and seems to possess modest antiandrogenic activity. The prolonged use of ranitidine has been associated with gynecomastia and impotence.
SECOND-GENERATION HISTAMINE BLOCKERS
Currently, a large number of HZ-receptor antagonists are in various stages of pharmacological development and clinical testing. These compounds represent further refinements in potency, selectivity, and duration of action relative to currently available drugs. Famotidine, the first of the agents, has rapidly achieved clinical acceptance. Several more of these agents appear destined for clinical introduction in the next several years.
The first new H,-receptor blocker is famotidine. Famotidine is based on a thiazole ring structure in contrast to the imidazole ring of cimetidine or the furan ring of ranitidine. Famotidine has the advantages of a greater potency and longer duration of action than either cimetidine or ranitidine. In normal human subjects, a ZO-mg dose of famotidine resulted in 90% suppression of pentagastrinstimulated gastric acid output, compared with a 55% suppression of acid output by 300 mg of cimetidine.""
In addition, the duration of acid suppression was prolonged relative to the actions of cimetidine.
Pentagastrin
The volume of gastric secretion was also significantly decreased. McCallum and co-workers have reported that 5 mg famotidine is equipotent with 300 mg of cimetidine but with a longer duration of action.6" Famotidine has also been demonstrated to inhibit acid secretion stimulated by histamine, gastrin, or 2-deoxyglucose. Famotidine does not appear to bind to hepatic microsomal enzyme systems as avidly as cimetidine and, in contrast to cimetidine, does not affect the pharmacokinetics of diazepam (which is eliminated by hepatic metabolism1 or procainamide (eliminated by tubular secretion1 .61 Three large, prospective, controlled studies have compared famotidine to ranitidine in the short-term treatment of acute ulceration (Table 2). The results were remarkably similar for all three studies.6"-6' Endoscopically documented healing rates of greater than 90% were observed at 8 weeks when famotidine was administered at 40 mg once per day. Healing rates were not significantly different between patients who received famotidine and patients who received ranitidine 150 mg twice per day. When famotidine was administered at a dose of 20 mg at bedtime as maintenance therapy, the cumulative U-month relapse rate was 23.3% .65 Administration of famotidine at a dose of 40 mg resulted in a similar 12-month relapse rate of 24.8%, while patients treated with placebo had significantly greater ulcer recurrence rates (56.8% 1. On the basis of these data, a dose of 20 mg at bedtime has been proposed as a maintenance dose for famotidine. The postmarketing safety record of famotidine is not as extensive as that of cimetidine or ranitidine."5
Case reports suggest, however, that the nature and frequency of adverse effects associated with famotidine will be similar to those observed with cimetidine and ranitidine.
Etintidine, a new HZ-receptor antagonist recently entered into clinical trials, may circumvent some of the problems associated with cimetidine use. Etintidine is structurally similar to cimetidine, differing only by the addition of an ethynyl group to the side chain of the parent compound.
Animal studies have indicated that, on a molar basis, etintidine is approximately twice as potent as cimetidine.66 In patients with duodenal ulcer disease, a 300-mg dose of etintidine was significantly more effective than the same dose of cimetidine in suppressing meal-stimulated acid secretion."' The mean acid reduction at 4 hours after administration of the drug was 94% for etintidine in comparison to 80% for cimetidine. At these doses, other pharmacokinetic parameters were not significantly different. The greatest difference between etintidine and cimetidine is illustrated by the dose response curves, which differ in both position and slope (Fig 5) 
CHEMISTRY
Omeprazole is a substituted benzimidazole (Fig 6) .
PHARMACOKINETICS
Short-term studies in normal subjects have demonstrated that oral doses of omeprazole from 20 to 30 mg result in almost complete inhibition of maximally stimulated gastric secretion within 6 hours.'" At 24 hours after administration of this dose, 60% to 70% reduction in stimulated acid secretion persists.76 Omeprazole administration at 30 mg once per day reduces nocturnal acidity by approximately 75% while 40 mg once daily has been reported to reduce 24-hour median acid secretion by almost 100% .7i,i8 Repeated daily doses of omeprazole result in increasing inhibitory action on gastric secretion which stabilizes after about 3 days.'Y,80
Because of its pKa, omeprazole is slightly soluble in water of neutral pH, but very soluble in alkaline solutions.
Omeprazole is degraded very rapidly in aqueous solutions of low pH and, as a result, various oral formulations have been developed to limit intragastric degradation.
These formulations also serve to improve systemic bioavailability. The mean time to attain maximum plasma concentrations is highly dependent on the formulation of the drug. In general, maximal concentrations are achieved between 2 and 5 hours when enteric-coated granules of the drug are employed. Open studies in patients with endoscopically proven duodenal ulcers have demonstrated complete healing in 80% of patients after 2 weeks and in 95% of patients after 4 weeks of treatment with omeprazole at 30 to 40 mg once daily.85 At doses above 20 mg/day, a significant inhibition of peak acid output, marked relief of epigastric pain, and decreased need for supplemental antacid therapy have been demonstrated in several studies of patients with acute duodenal ulceration.
There does not appear to be any clinically significant advantage in increasing the omeprazole dose to greater than 20 mg daily. In addition, the inclusion of an initial loading dose does not influence the rate of ulcer healing or the rapidity of symptomatic relief compared with the same treatment not preceded by loading dose.86,87 As with most other forms of therapy, duodenal ulcers are more difficult to heal in patients who smoke compared to nonsmokers. Omeprazole 20 to 40 mg daily has been compared with ranitidine 150 mg twice daily, and cimetidine 1,000 mg/day in patients with acute duodenal ulceration. At 4 weeks after initiation of therapy, 92% to 100% of ulcers treated with omeprazole were healed by endo- Hyperplasia of oxyntic mucosal cells has also been observed in dogs and in mice, although in these species the differences are much less notable than in rats, and tumor production has not been observed.
Larsson and coworkers have noted that enterochromaffin-like cell hyperplasia in the rat is directly correlated with elevated circulating gastrin levels."J The degree of hypergastrinemia is, in turn, dependent on the degree of gastric acid inhibition produced by omepra- 
CZZEMZSTRY
Pirenzepine is a pyrido-benzodiazepine compound (Fig 7) . The drug is structurally similar to imipramine. However, unlike imipramine, it is without central nervous system activity because of poor penetration of the blood/brain barrier.
PHARMACOZUNETZCS
Like the classic antimuscarinic drugs, pirenzepine demonstrates dose-related anticholinergic activity in both animals and in man. However, unlike the classical drugs, pirenzepine inhibits gastric acid secretion at doses which do not significantly affect salivation, heart rate, ocular function, urinary bladder function, or gastrointestinal motility. The relatively low nongastric anticholinergic activity of pirenzepine is reflected by the lower incidence of undesirable anticholinergic side effects in therapeutic trials of the drug. In studies involving both animals and man, pirenzepine administered orally, subcutaneously, or intravenously, produced dose-de- pendent inhibition of gastric acid secretion stimulated by pentagastrin, histamine, bethanechol, or a test meal.'"' Pirenzepine markedly inhibits gastric acid secretion due to vagal stimuli such as sham feeding, insulin-induced hypoglycemia, or fundic distention."' It is somewhat less effective in inhibiting the effects of direct stimuli such as histamine and pentagastrinl" As with most anticholinergic agents, the reduction of acid secretion produced by pirenzepine is due to a decrease in the volume of gastric secretion rather than acid concentration.103
In normal control subjects, orally administered pirenzepine at doses of 50 mg and 100 mg reduced total nocturnal acid output by 32% and 41%, respectively."" One hour after a 50-mg oral dose, basal gastric acid output was decreased by 71% and mealstimulated acid output was decreased by 51%. Antisecretory activity is still decreased by approximately 45% at 4 hours after oral administration.
Intravenously administered pirenzepine has been demonstrated Curr Probl Surgj January 1989 3.5
to produce modest decreases in the secretion of pancreatic enzymes such as trypsin, lipase, amylase, and chymotrypsin. In addition, a modest increase in bicarbonate secretion by the pancreas has been noted. Clinically significant alterations in pancreatic exocrine function have not been reported, however, nor have clinically important alterations in pancreatic endocrine function been observed. Pirenzepine does not appear to affect basal or postprandial concentrations of serum insulin or glucagon. In patients with duodenal ulcer, intravenous administration of pirenzepine reduces basal secretion of pancreatic polypeptide and decreases the rise in pancreatic polypeptide stimulated by sham feeding."" Pirenzepine has minimal effects on serum gastrin concentrations.
Intravenously administered single doses of pirenzepine have been reported to significantly decrease the volume of gastric mucous output, but the drug does not appear to alter the composition or function of the gastric mucous secretion. The clinical significance of these findings relating to gastric mucous is unknown.
A dose-dependent decrease in pepsin output has also been reported following administration of intravenous pirenzepine.
When administered orally, therapeutic doses of pirenzepine do not increase heart rate significantly.*"
In patients with duodenal ulcers, a dose-related reduction in salivation has been noted when therapeutic doses of pirenzepine were administered intravenously. The effect was much less marked and of shorter duration than that occurring after equipotent doses of atropine.80 Symptomatic drying of the mucous membranes is unusual, however. In a &day comparative trial, orally administered pirenzepine 50 mg twice daily was associated with no ocular symptoms.'"" Pirenzepine does not change intraocular pressure in subjects with open or closed angle glaucoma, and, unlike other classic antimuscarinic agents, pirenzepine is not contraindicated in patients with glaucoma. Despite the structural similarity of pirenzepine and tricyclic antidepressant drugs, pirenzepine does not cross the blood/brain barrier and has not been reported to exhibit central nervous system effects.107"oX Orally administered pirenzepine has not been reported to affect residual urinary volume, tone of the bladder wall, or bladder emptying, even in patients with symptomatic prostatic hypertrophy. At usual therapeutic doses, oral pirenzepine does not slow gastric emptying of a liquid or solid meal in normal healthy subjects.lo7' lo9 Pirenzepine at 25 to 7.5 mg daily has not been reported to have any significant effect on esophageal function in healthy subjects.110 With oral administration of the drug, peak plasma concentrations of pirenzepine are observed 2 to 3 hours after administration. The peak plasma concentration is linearly related to the dosage."' With repeated oral doses in man, plasma concentrations have been reported to increase for the first few days, but remain constant there-
The mean bioavailability of pirenzepine administered orally approximates 25% .ll', '13 Bioavailability has been reported to decrease when the drug is taken with a meal.
Studies in animals have demonstrated that pirenzepine is distributed widely in the body, being found in all organs with the exception of the central nervous system. As mentioned previously, pirenzepine does not pass the blood/brain barrier. In addition, the drug does not appear to pass the placental barrier. No data are currently available regarding the excretion of pirenzepine into human breast milk.
Very little pirenzepine is metabolized. By 4 days after oral administration, 90% of the administered dose can be recovered in the feces; approximately 10% of the dose is excreted unchanged in the urine.'13 Total plasma clearance approximates 250 cc/min. The mean plasma half-life of pirenzepine is approximately 12 hours and is not influenced by the route of administration.
CLINICAL USE
Several studies have demonstrated that pirenzepine accelerates the healing of duodenal ulcers. The rate of ulcer healing in most studies is clearly dose-related.
Ulcers have been reported to heal in 52% of patients treated with 50 to 75 mg of pirenzepine daily, and in 70% of patients treated with 100 to 150 mg per day.gy In a review by Carmine and Brogden, duodenal ulcers were noted to heal in 32% to 75% of patients taking placebos."
In similar studies, in 45% to 75% of those treated with less than 100 mg/day of pirenzepine, ulcers were healed. However, in 70% to 90% of patients treated with pirenzepine 100 to 150 mg/day over a 4-week period, ulcers were healed. These authors concluded that pirenzepine at doses of less than 100 mg/day was ineffective in treating patients with acute peptic ulceration.
Numerous studies have compared relative efficacy of pirenzepine and cimetidine in the treatment of patients with acute ulceration. Most of these trials have not demonstrated a significant difference between the two agents in healing rates. Although results differ from author to author, within each study ulcer healing rates are generally similar following 4 or 6 weeks treatment with pirenzepine 100 to 150 mg/day or cimetidine 1,000 mg/day." Although ultimate healing rates are similar for both drugs, symptomatic remission is usually faster in patients treated with cimetidine.
Pirenzepine 100 mg/day has also been demonstrated to be equivalent to ranitidine 300 mg/day in the treatment of patients with acute peptic ulceration."' Two studies have demonstrated that pirenzepine at a dose of 30 to 50 mg/day was ineffective as chronic maintenance therapy. Re-lapse rate for patients receiving pirenzepine
was not different from placebo-treated or untreated patients. Maintenance therapy with higher pirenzepine doses has not been reported. Because of these considerations, the usual oral adult dose of pirenzepine for the treatment of patients with acute duodenal ulceration is 100 mgday in divided doses at bedtime and before the morning meal. The total daily dose may be increased to 150 mg/day in two divided doses as needed. Pirenzepine may be combined with cimetidine or ranitidine, as this combination appears to potentiate the antisecretory effects of HZ-receptor blockade. Anticholinergic therapy should be continued until ulcer healing occurs, as documented by repeat endoscopy at 4 to 8 weeks.
SIDE EFFECTS
In short-term control studies, pirenzepine has been demonstrated to be an effective and safe drug. Discontinuation, because of unpleasant side effects, is unusual and has occurred in approximately 2% of patients."
The most frequently reported side effect of pirenzepine therapy is dry mouth. This symptom occurs in approximately 14% of patients receiving 100 to 150 mg/day. The symptom is usually of mild-to-moderate severity and requires withdrawal of the drug in only 0.5% of treated patients. The incidence of dry mouth is clearly dose-dependent and decreasing dosage is usually followed by cessation of the unpleasant symptom. Ocular disturbances, particularly blurred vision, are another antimuscarinic effect of pirenzepine experienced by approximately 1% of patients receiving 100 mgday. This side effect is also dose-dependent; 5.6% of patients taking 150 mg/day will complain of blurred vision.115 The symptom is severe enough to require discontinuation in approximately 1% of patients at the higher dose range. Clinically important effects on the gastrointestinal tract are unusual. In most instances, the relationship to the selective antimuscarinic action of pirenzepine is unclear. While 3.3% of patients complain of constipation, a similar 3.4% experience diarrhea during pirenzepine therapy.'15 Only 0.5% of the patients required treatment stoppage because of adverse gastrointestinal effects. Central nervous system effects are unusual and rarely require termination of treatment. Other adverse effects, such as skin reactions, allergy, and nausea, are unusual. Cardiovascular side effects are rare. When pirenzepine 100 to 150 mg/day and cimetidine 1,000 mgday were compared, the incidence of side effects such as headache, dizziness, endocrinologic abnormalities, allergic reactions, and central nervous system symptoms was slightly greater with a cimetidine group;'15 however, the relative incidence of dry mouth and blurred vision is clearly higher in patients receiving pirenzepine.
Long-term studies in patients receiving pirenzepine have not reported any clinically significant adverse effects, nor have significant abnormalities in laboratory tests been reported in these patients.l15
CXTOPROTECTIVE AGENTS
PROSTAGLANDINS
The term "cytoprotection" was coined by .Jacobsonllfi and by Robert"' to denote the phenomenon by which the administration of prostaglandins confers gastric mucosa protection from ethanol, strong acids, strong alkali, or harmful physical agents. In the "cytoprotected" animals, the gastric mucosa remains remarkably intact after instillation of these agents which normally cause severe damage."" In the present context, "c-ytoprotection" is used to mean protection of the gastric mucosa from gross or histologic damage. An agent is said to have a cytoprotective effect if it protects against damage at doses that are lower than the threshold dose for inhibition of acid secretion.
Prostaglandins are one of several classes of compounds with cytoprotective action (Table 3) .
Chemistry and Pharmacokinetics Prostaglandins are 20-carbon oxygenated fatty acids. They are synthesized from dietary essential fatty acids through the action of cyclooxygenase.
This cyclooxygenase pathway also results in the synthesis of prostacyclin and thromboxanes (Fig 8) . All the prostaglandins have a cyclopentane ring, and, depending on the structure of the ring, they are classified as prostaglandin A, B, C, D, E, and F (Fig 9) . The compounds also have upper and lower carbon side-chains. Depending on the number of double-bonds present in the upper and lower side-chains, the prostaglandins are further designated 1, 2, and 3 (Fig 10) . The prostaglandins of medical interest The clinical applications and implications of prostaglandin therapy in patients with acid peptic disease are summarized in Table 4 .
The-major side effect of prostaglandin therapy is diarrhea."' Some 30% to 40% of patients will experience some loosening of their stool but frank diarrhea occurs only in about 5%. The diarrhea in most cases has been transient and has stopped despite continued administration of the drug. In less than 0.5% of patients, prostaglandin analogues have to be stopped because of severe diarrhea.
The other two side effects of prostaglandins are uterine bleeding and the potential for spontaneous abortions. In a West German The major difference between colloidal bismuth and cimetidine is the significantly lower ulcer recurrence rate after cessation of bismuth therapy relative to that observed of cessation of cimetidine.
This observation suggests that colloidal bismuth may be capable of changing the natural history of duodenal ulcer disease in a manner not observed with cimetidine.
Both bictropeptide bismuthate1""'135 and tripotassium dicitratobismuthate have been shown to heal gastric ulcers significantly better than placebo (79% to 90% vs. 30% to 35% at 4 weeks). While there is anticipation that colloidal bismuth may provide a more effective therapy of gastric ulcer than cimetidine, significantly large clinical trials are not available to sustain this assumption.
Side Eficts
No serious side effects have been reported with the use of colloidal bismuth compounds.
However, bismuth causes blackening of the stools which may be confused with melena. It also causes the tongue to turn black. Although innocuous, this side effect is cosmetically unappealing.
SUCRALFATE Chemistry and Mechanism
of Actions Sucralfate is the basic aluminum salt of sulfated sucrose. In the acid medium of the stomach, it becomes viscous and adheres to defective mucosa to form a protective barrier.136 Thus, the ulcer bed becomes protected from continuing exposure to acid and pepsin. In addition to this barrier action, sucralfate possesses several potentially beneficial actions: (1) it neutralizes small amounts of acid (1 gm of sucralfate buffers 13 mEq of H+ at pH 4.01; (21 it inhibits the action of pepsin; (31 it binds bile-salts, leading to their depletion from the gastric lumen; 14) it stimulates mucus secretion. Sucralfate is one of the drugs said to have "cytoprotective"
properties. Whether this property is due solely to these listed actions of the drug, or whether it also has additional effects on the rate of renewal of surface epithelial cells and prostaglandin synthesis, has not been conclusively shown. A major decline has occurred in the incidence of surgery for peptic ulcer disease. Two factors are responsible: a decrease in the incidence of peptic ulcer disease itself and the introduction of effective pharmacologic agents. Of these two factors, the latter has had the more significant effect on ulcer surgery, with the decline almost entirely in elective ulcer surgery. It is only on rare occasions now that patients are referred to surgery because of intractability of the disease. While elective operations have declined, the number of operations performed for complications of peptic ulcer (perforation, bleeding, and obstruction1 has remained relatively stable. Many surgeons feel the type of peptic ulcer they are now called on to treat operatively is more virulent, with a higher incidence of giant ulcers, more severe duodenal deformity, and more extensive penetration and inflammation.
This clinical impression, however, remains only an impression, and there are no clinical studies to support it. The challenge for surgeons has now become to mesh the currently avail-able operative therapies to the widening array of effective pharmacologic agents.
From the patient's perspective, the most important issue is pain control. The currently available HZ-receptor antagonists and newer agents such as omeprazole are able to provide relief of pain in the large majority of patients (i'O%-90%) within 2 to 4 weeks of initiation of treatment.
Symptomatic control does not seem to be compromised by a history of recurrence.
Relief of pain should not be equated with complete healing of ulceration, however, nor does absence of pain eliminate the possibility of complication of ulcer disease.
A high proportion of ulcer patients who bleed do so during a recurrence, and patients who have bled once have a higher risk of bleeding again. Boyd and colleagues have estimated that the lifetime risk of hemorrhage for duodenal ulcer patients who have not had surgery and who do not receive maintenance drug therapy approximates 39% for men and 36% for women.lJ7 In contrast, the overall proportion of recurrent ulcers that bleed during maintenance therapy is approximately 2% during the first year.14' Thus a strong argument can be made, from the standpoint of hemorrhage, for continued maintenance drug therapy after initial healing of ulcers. Recurrent ulcer hemorrhage of a degree that requires hospitalization, or transfusion, or active endoscopic treatment should be considered an indication for operation.
Of course, massive hemorrhage should always prompt consideration for operative intervention. Although perforation is less common than hemorrhage, the rate of perforation has not decreased markedly since the introduction of effective HZ-receptor therapy. The lifetime risk of perforation for untreated patients approximates 10% .14' Ulcer perforation appears to be rare during maintenance therapy for individuals without a history of antecedent perforation. However, perforation remains an indication for definitive anti-ulcer surgery for those patients with historical or anatomic evidence of chronic peptic ulcer disease.
The reported incidence of symptomatic pyloric stenosis is variable, but may approximate 10% in untreated individuals. None of the agents reviewed can be expected to have beneficial effect on the chronic cicatrization causing pyloric obstruction. Pyloric stenosis remains a firm indication for operative intervention. With the decline of peptic ulcer surgery, surgical residents have less opportunity to learn all the details of vagotomy or gastric resection. The introduction of proximal gastric vagotomy in the treatment of duodenal ulcer coincided with the sharp decline in ulcer surgery. As a result, many surgical residents complete their training without a broad exposure to anti-ulcer surgery. As mentioned previously, the major effect of the advent of potent ulcer drugs has been on elective and not emergency operations for the disease. It is possible that this, too, may change in the future. As better and safer cytoprotective drugs are discovered, the natural history of peptic ulcer in individual patients treated will be altered. Such drugs also may be more efficacious in maintenance therapy. Both of these factors may contribute to lowering the incidence of complications in peptic ulcer disease and, hence, emergent surgery for peptic ulcer. 
